EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients

Milo Gatti iD, Matteo Rinaldi iD, Cristiana Laici, Simone Ambretti, Antonio Siniscalchi, Pierluigi Viale, Federico Pea iD

Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2586-2590

DOI: 10.1093/jac/dkae261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 01.08.2024. Verfasst von Milo Gatti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Boronic Acids, Meropenem, Biliary Tract Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyse the biliary pharmacokinetics/pharmacodynamics (PK/PD) of continuous infusion (CI) meropenem-vaborbactam (MEM-VBM) in a case series of orthotopic liver transplant (OLT) recipients being treated for Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) related biliary tract infections (BTIs) or as preemptive therapy of KPC-Kp rectal colonization.

Methods

Critical OLT recipients receiving CI MEM-VBM (2 g/2 g q8h over 8 h) because of KPC-Kp related BTIs or as preemptive therapy of KPC-Kp rectal colonization, having Kehr’s tube positioned and undergoing simultaneous therapeutic drug monitoring of MEM and VBM in plasma and bile were retrospectively assessed. Bile-to-plasma ratio of free steady-state concentrations (fCss) of MEM and VBM was used for assessing biliary penetration. Optimal joint MEM-VBM PK/PD target attainment was defined as MEM fCss/MIC ratio >4 coupled with VBM free area under time–concentration curve (fAUC)/threshold concentration (CT) ratio >24.

Results

Overall, four critical OLT recipients were included. Median bile-to-plasma ratio was 0.32 for MEM (range 0.21–0.79) and 0.40 for VBM (range 0.20–0.77). Biliary MEM-VBM joint PK/PD target attainment was optimal in 3/4 OLT recipients and quasi-optimal in the other one.

Conclusions

The 1:1 proportion between MEM and VBM concentrations was maintained unchanged in the bile, allowing us to assume that the efficacy of MEM-VBM may be appropriate even in the treatment of BTIs. CI administration was an effective strategy for attaining aggressive biliary joint PK/PD targets against pathogens with an MIC up to 2 mg/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationBoronic AcidsMeropenemBiliary Tract DiseasesKlebsiella InfectionsBiliary TractDrug Combinationsbeta-Lactamase InhibitorsKlebsiella pneumoniaeTransplantsArea Under CurveTissue DistributionDrug MonitoringCritical IllnessMicrobial Sensitivity TestsHumansMaleFemaleAdultMiddle AgedRetrospective StudiesInfusions, IntravenousBilebeta-LactamasesBacterial Proteins

Substanzen

Boronic AcidsDrug CombinationsMeropenembeta-Lactamase Inhibitorsbeta-LactamasesBacterial Proteinsmeropenem and vaborbactamHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Anesthesiology, Department of Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Operative Unit of Microbiology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Milo Gatti, Matteo Rinaldi, Federico Pea

Zitieren

APA

Gatti, M., Rinaldi, M., Laici, C., Ambretti, S., Siniscalchi, A., Viale, P., & Pea, F. (2024). Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients. Journal of Antimicrobial Chemotherapy, 79(10), 2586-2590. https://doi.org/10.1093/jac/dkae261

Vancouver

Gatti M, Rinaldi M, Laici C, Ambretti S, Siniscalchi A, Viale P, et al. Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients. Journal of Antimicrobial Chemotherapy. 2024;79(10):2586-2590. doi:10.1093/jac/dkae261

BibTeX
@article{Gatti2024,
  author = {Gatti, Milo and Rinaldi, Matteo and Laici, Cristiana and Ambretti, Simone and Siniscalchi, Antonio and Viale, Pierluigi and Pea, Federico},
  title = {Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {10},
  pages = {2586--2590},
  doi = {10.1093/jac/dkae261}
}
Kostenlos starten →